46 related articles for article (PubMed ID: 24754926)
1. Distribution of the phosphatidylinositol 3-kinase inhibitors Pictilisib (GDC-0941) and GNE-317 in U87 and GS2 intracranial glioblastoma models-assessment by matrix-assisted laser desorption ionization imaging.
Salphati L; Shahidi-Latham S; Quiason C; Barck K; Nishimura M; Alicke B; Pang J; Carano RA; Olivero AG; Phillips HS
Drug Metab Dispos; 2014 Jul; 42(7):1110-6. PubMed ID: 24754926
[TBL] [Abstract][Full Text] [Related]
2. Combining "Bottom-up" and "Top-down" Approaches to Assess the Impact of Food and Gastric pH on Pictilisib (GDC-0941) Pharmacokinetics.
Lu T; Fraczkiewicz G; Salphati L; Budha N; Dalziel G; Smelick GS; Morrissey KM; Davis JD; Jin JY; Ware JA
CPT Pharmacometrics Syst Pharmacol; 2017 Nov; 6(11):747-755. PubMed ID: 28748626
[TBL] [Abstract][Full Text] [Related]
3. Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation.
Ang JE; Pandher R; Ang JC; Asad YJ; Henley AT; Valenti M; Box G; de Haven Brandon A; Baird RD; Friedman L; Derynck M; Vanhaesebroeck B; Eccles SA; Kaye SB; Workman P; de Bono JS; Raynaud FI
Mol Cancer Ther; 2016 Jun; 15(6):1412-24. PubMed ID: 27048952
[TBL] [Abstract][Full Text] [Related]
4. Molecular imaging of drug transit through the blood-brain barrier with MALDI mass spectrometry imaging.
Liu X; Ide JL; Norton I; Marchionni MA; Ebling MC; Wang LY; Davis E; Sauvageot CM; Kesari S; Kellersberger KA; Easterling ML; Santagata S; Stuart DD; Alberta J; Agar JN; Stiles CD; Agar NY
Sci Rep; 2013 Oct; 3():2859. PubMed ID: 24091529
[TBL] [Abstract][Full Text] [Related]
5. Integrated mapping of pharmacokinetics and pharmacodynamics in a patient-derived xenograft model of glioblastoma.
Randall EC; Emdal KB; Laramy JK; Kim M; Roos A; Calligaris D; Regan MS; Gupta SK; Mladek AC; Carlson BL; Johnson AJ; Lu FK; Xie XS; Joughin BA; Reddy RJ; Peng S; Abdelmoula WM; Jackson PR; Kolluri A; Kellersberger KA; Agar JN; Lauffenburger DA; Swanson KR; Tran NL; Elmquist WF; White FM; Sarkaria JN; Agar NYR
Nat Commun; 2018 Nov; 9(1):4904. PubMed ID: 30464169
[TBL] [Abstract][Full Text] [Related]
6. High-throughput glycolytic inhibitor discovery targeting glioblastoma by graphite dots-assisted LDI mass spectrometry.
Shi R; Pan P; Lv R; Ma C; Wu E; Guo R; Zhao Z; Song H; Zhou J; Liu Y; Xu G; Hou T; Kang Z; Liu J
Sci Adv; 2022 Feb; 8(7):eabl4923. PubMed ID: 35171681
[TBL] [Abstract][Full Text] [Related]
7. Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo.
Lopez S; Schwab CL; Cocco E; Bellone S; Bonazzoli E; English DP; Schwartz PE; Rutherford T; Angioli R; Santin AD
Gynecol Oncol; 2014 Nov; 135(2):312-7. PubMed ID: 25172762
[TBL] [Abstract][Full Text] [Related]
8. Decreased affinity for efflux transporters increases brain penetrance and molecular targeting of a PI3K/mTOR inhibitor in a mouse model of glioblastoma.
Becker CM; Oberoi RK; McFarren SJ; Muldoon DM; Pafundi DH; Pokorny JL; Brinkmann DH; Ohlfest JR; Sarkaria JN; Largaespada DA; Elmquist WF
Neuro Oncol; 2015 Sep; 17(9):1210-9. PubMed ID: 25972455
[TBL] [Abstract][Full Text] [Related]
9. First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.
Sarker D; Ang JE; Baird R; Kristeleit R; Shah K; Moreno V; Clarke PA; Raynaud FI; Levy G; Ware JA; Mazina K; Lin R; Wu J; Fredrickson J; Spoerke JM; Lackner MR; Yan Y; Friedman LS; Kaye SB; Derynck MK; Workman P; de Bono JS
Clin Cancer Res; 2015 Jan; 21(1):77-86. PubMed ID: 25370471
[TBL] [Abstract][Full Text] [Related]
10. Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial.
Wen PY; Touat M; Alexander BM; Mellinghoff IK; Ramkissoon S; McCluskey CS; Pelton K; Haidar S; Basu SS; Gaffey SC; Brown LE; Martinez-Ledesma JE; Wu S; Kim J; Wei W; Park MA; Huse JT; Kuhn JG; Rinne ML; Colman H; Agar NYR; Omuro AM; DeAngelis LM; Gilbert MR; de Groot JF; Cloughesy TF; Chi AS; Roberts TM; Zhao JJ; Lee EQ; Nayak L; Heath JR; Horky LL; Batchelor TT; Beroukhim R; Chang SM; Ligon AH; Dunn IF; Koul D; Young GS; Prados MD; Reardon DA; Yung WKA; Ligon KL
J Clin Oncol; 2019 Mar; 37(9):741-750. PubMed ID: 30715997
[TBL] [Abstract][Full Text] [Related]
11. Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-β tyrosine kinase inhibitor, in patients with recurrent glioblastoma.
Batchelor TT; Gerstner ER; Ye X; Desideri S; Duda DG; Peereboom D; Lesser GJ; Chowdhary S; Wen PY; Grossman S; Supko JG
Neuro Oncol; 2017 Apr; 19(4):567-575. PubMed ID: 27663390
[TBL] [Abstract][Full Text] [Related]
12. From signalling pathways to targeted therapies: unravelling glioblastoma's secrets and harnessing two decades of progress.
Dewdney B; Jenkins MR; Best SA; Freytag S; Prasad K; Holst J; Endersby R; Johns TG
Signal Transduct Target Ther; 2023 Oct; 8(1):400. PubMed ID: 37857607
[TBL] [Abstract][Full Text] [Related]
13. How Much is Enough? Impact of Efflux Transporters on Drug delivery Leading to Efficacy in the Treatment of Brain Tumors.
Zhang W; Oh JH; Zhang W; Rathi S; Le J; Talele S; Sarkaria JN; Elmquist WF
Pharm Res; 2023 Nov; 40(11):2731-2746. PubMed ID: 37589827
[TBL] [Abstract][Full Text] [Related]
14. PI3K/mTOR Dual Inhibitor Pictilisib Stably Binds to Site I of Human Serum Albumin as Observed by Computer Simulation, Multispectroscopic, and Microscopic Studies.
Yang H; Ma Y; Zhang H; Ma J
Molecules; 2022 Aug; 27(16):. PubMed ID: 36014303
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic strategies of glioblastoma (GBM): The current advances in the molecular targets and bioactive small molecule compounds.
Liu H; Qiu W; Sun T; Wang L; Du C; Hu Y; Liu W; Feng F; Chen Y; Sun H
Acta Pharm Sin B; 2022 Apr; 12(4):1781-1804. PubMed ID: 35847506
[TBL] [Abstract][Full Text] [Related]
16. Targeting RTK-PI3K-mTOR Axis in Gliomas: An Update.
Colardo M; Segatto M; Di Bartolomeo S
Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34063168
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of Resistance to PI3K Inhibitors in Cancer: Adaptive Responses, Drug Tolerance and Cellular Plasticity.
Wright SCE; Vasilevski N; Serra V; Rodon J; Eichhorn PJA
Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33810522
[TBL] [Abstract][Full Text] [Related]
18. ABC Transporters at the Blood-Brain Interfaces, Their Study Models, and Drug Delivery Implications in Gliomas.
Gomez-Zepeda D; Taghi M; Scherrmann JM; Decleves X; Menet MC
Pharmaceutics; 2019 Dec; 12(1):. PubMed ID: 31878061
[TBL] [Abstract][Full Text] [Related]
19. High-resolution mapping of fluoroquinolones in TB rabbit lesions reveals specific distribution in immune cell types.
Blanc L; Daudelin IB; Podell BK; Chen PY; Zimmerman M; Martinot AJ; Savic RM; Prideaux B; Dartois V
Elife; 2018 Nov; 7():. PubMed ID: 30427309
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of PI3K signalling increases the efficiency of radiotherapy in glioblastoma cells.
Hasslacher S; Schneele L; Stroh S; Langhans J; Zeiler K; Kattner P; Karpel-Massler G; Siegelin MD; Schneider M; Zhou S; Grunert M; Halatsch ME; Nonnenmacher L; Debatin KM; Westhoff MA
Int J Oncol; 2018 Nov; 53(5):1881-1896. PubMed ID: 30132519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
